Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Board of
Directors approved the termination of Shahram K. Rabbani’s services as
the Company’s Secretary and Treasurer, respectively, effective
immediately. At this time, Mr. Rabbani will continue to serve as a
Director of the Company.
The Company also announced today that its Board of Directors approved
the appointment of Dr. Elazar Rabbani to serve as Secretary and the
appointment of Barry W. Weiner to serve as Treasurer, effective
immediately. Dr. Elazar Rabbani is the Company’s current Chairman of the
Board and Chief Executive Officer and Mr. Barry Weiner currently serves
as the current President, Chief Financial Officer, Principal Accounting
Officer and as a member of the Board of Directors of the Company.
About Enzo
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and
biotechnology company focused on harnessing biological process to
develop research tools, diagnostics and therapeutics, and serves as a
provider of both routine and esoteric test services to the medical
community. Since its founding in 1976, the Company’s strategic focus has
been on the development of enabling technologies in the life sciences
field. Enzo Life Sciences develops, produces and markets proprietary
labeling and detection products for gene expression analysis, nucleic
acid detection, protein biochemistry, and cellular analysis, among
others. Its catalog of over 40,000 products serve the molecular
biology, cellular biochemistry, drug discovery and pathology research
markets worldwide. Enzo Clinical Labs division provides laboratory
services for a growing roster of physicians in the New York Metropolitan
area, as well as New Jersey and parts of Pennsylvania. Its tests
include, in addition to routine tests, capabilities for detecting
molecular infectious disease, molecular oncology, autoimmune disorders
and genetics. Enzo Clinical Labs also provides clinical diagnostic
services that allows Enzo to capitalize on its extensive advanced
molecular and cytogenetic capabilities and the broader trends in
predictive and personalized diagnostics. Enzo Therapeutics is a
biopharmaceutical venture that has developed multiple novel approaches
in the areas of gastrointestinal, infectious, ophthalmic and metabolic
diseases. It has focused its efforts on developing treatment regimens
for diseases and conditions for which current treatment options are
ineffective, costly, and/or cause unwanted side effects. In the course
of the company’s research and development activities, Enzo has developed
a substantial portfolio of intellectual property assets, with over 240
issued patents worldwide and more than 200 pending patent applications.
Safe Harbor Statement
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
